A promising collection of studies suggests taking antivirals such as Paxlovid during an infection could reduce the risk of developing long COVID.
Disiplin ilmiah, gaya jurnalistik
Artikel-artikel mengenai COVID antivirals
Menampilkan semua artikel
Two antiviral drugs are available in Australia, but one is prescribed more routinely. Here’s what you need to know as we navigate the eighth COVID wave.
People in disadvantaged communities are less likely to access COVID antivirals. That needs to change.
In particular, a drug called Evusheld could offer protection for people who are vulnerable – but the UK isn’t offering it.
Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.
This guidance replaces previous conditional recommendations for the use of these drugs and is based on emerging evidence that they’re not likely to work against omicron.
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
After testing positive for COVID, your medicine prescription will depend on the severity of your symptoms and any other health conditions you have.
Based on certain criteria, New Zealand is clearly ‘winning’. But getting policy settings right over the long haul is about more than just having the most favourable assessment on selected criteria.
Here’s who is eligible, the benefits and side effects to consider.
An infectious disease doctor discusses the use, benefits and availability of a drug to prevent severe COVID-19.
Earlier detection and treatment of COVID-19 by health care providers in pharmacies could help prevent surges in infection rates and severe illness.
Paxlovid is one potential COVID drug for use at home. The idea is these can potentially be prescribed at the first sign of infection to prevent serious illness and death.
Kontributor teratas
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Associate Professor and Chief Health Officer - COVID and Health Emergencies, Burnet Institute
-
Pharmacist and PhD Candidate, University of Sydney
-
Professor of Cancer Virology, University of Leeds
-
Post doctoral researcher and medical epidemiologist, The Peter Doherty Institute for Infection and Immunity
-
Associate Professor in Viral Immunology, University of Birmingham
-
Professor of general practice, Bond University
-
Monash University
-
A/Professor, paediatrician, infectious diseases physician and clinical pharmacologist, Murdoch Children's Research Institute
-
NHMRC Leadership Fellow UQ Centre for Clinical Research, The University of Queensland
-
Senior Lecturer in Pharmacy and Pharmacology, Head of Breast Cancer Targeting and Drug Delivery Laboratory, University of Sydney
-
Associate Professor in Clinical Immunology, University of Birmingham, University of Birmingham
-
PhD candidate at The Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Assistant Professor of Infectious Diseases, University of Virginia
